In vivo attenuation of myointimal hyperplasia using transforming growth factor-beta3 in an interposition graft model

Journal of Endovascular Therapy

Volumn 13, Issue 3, 2006, Pages 389-399

  Murphy, Michael O ^a   Ghosh, Jonathan ^a   Halka, Anatassi T ^a   Carter, Andrew ^a   Turner, Neil J ^a   Ferguson, Mark W J ^a   Kielty, Cay M ^a   Walker, Michael G ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Animal model; Caprine model; Experimental study; Graft failure; Interposition graft; Intimal hyperplasia; Polyurethane graft; Transforming growth factor beta

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN; COLLAGEN TYPE 8; ELASTIN; PLACEBO; POLYURETHAN; TRANSFORMING GROWTH FACTOR BETA3;

ADVENTITIA; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL GRAFT; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENERAL ANESTHESIA; GOAT; GRAFT FAILURE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE; STATISTICAL ANALYSIS;

ACTINS; ANASTOMOSIS, SURGICAL; ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAROTID ARTERY, COMMON; CELL PROLIFERATION; COLLAGEN TYPE VIII; ELASTIN; FEMALE; GOATS; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA3; VASCULAR PATENCY;

EID: 33751188929     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/06-1846.1     Document Type: Article

References (37)

1. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384-392.
2. Laird JR, Reiser C, Biamino G, et al. Excimer laser assisted angioplasty for the treatment of critical limb ischemia. J Cardiovasc Surg (Torino). 2004;45:239-248.
3. Veith FJ, Moss CM, Sprayregen S, et al. Preoperative saphenous venography in arterial reconstructive surgery of the lower extremity. Surgery. 1979;85:253-256.
4. Devine C, McCollum C. North West Femoro-Popliteal T rial Participants. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg. 2004;40:924-931.
5. Tai NR, Salacinski HJ, Edwards A, et al. Compliance properties of conduits used in vascular reconstruction. Br J Surg. 2000;87:1516-15124.
6. Griffiths GD, Nagy J, Black D, et al. Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytetrafluoroethylene bypass grafting. Br J Surg. 2004;91:560-562.
7. Trubel W, Schima H, Czerny M, et al. Experimental comparison of four methods of end-to-side anastomosis with expanded polytetrafluoroethylene. Br J Surg. 2004;91:159-167.
8. Heyligers JM, Arts CH, Verhagen HJ, et al. Improving small-diameter vascular grafts: from the application of an endothelial cell lining to the construction of a tissue-engineered blood vessel. Ann Vasc Surg. 2005;19:448-456.
9. Fujitani RM. Revision of the failing vein graft: outcome of secondary operations. Semin Vasc Surg. 1993;6:118-129.
10. Mills JL, Fujitani RM, Taylor SM. The characteristics and anatomic distribution of lesions that cause reversed vein graft failure: a five-year prospective study. J Vasc Surg. 1993;17:195-206.
11. Kingston PA, Sinha S, David A, et al. Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta type II receptor inhibits luminal loss and constructive remodeling after coronary angioplasty and enhances adventitial collagen deposition. Circulation. 2001;104:2595-2601.
12. Kingston PA, Sinha S, Appleby CE, et al. Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation. 2003;108:2819-2825.
13. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099.
14. Sottiurai VS, Sue SL, Feinberg EL, et al. Distal anastomotic intimal hyperplasia: biogenesis and etiology. Eur J Vasc Surg. 1988;2:245-256.
15. Ghosh J, Murphy MO, Turner N, et al. The role of transforming growth factor beta1 in the vascular system. Cardiovasc Pathol. 2005;14:28-36.
16. Sinha S, Kielty CM, Heagerty AM, et al. Upregulation of collagen VIII following porcine coronary artery angioplasty is related to smooth muscle cell migration not angiogenesis. Int J Exp Pathol. 2001;82:295-302.
17. Ghosh J, Baguneid M, Khwaja N, et al. Reduction of myointimal hyperplasia after arterial anastomosis by local injection of transforming growth factor beta3. J Vasc Surg. 2006;43:142-149.
18. Geary RL, Nikkari ST, Wagner WD, et al. Wound healing: a paradigm for lumen narrowing after arterial reconstruction. J Vasc Surg. 1998;27:96-108.
19. Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ. 2003;326:88-92.
20. Ferguson MW, O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2004;359:839-850.
21. Shah M, Revis D, Herrick S, et al. Role of elevated plasma transforming growth factor-beta1 levels in wound healing. Am J Pathol. 1999;154:1115-1124.
22. Medawar P. The rate of penetration of fixatives. J R Microsc Soc. 1941;61:46-57.
23. Martin I, Jakob M, Schafer D, et al. Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage. 2001;9:112-118.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
25. Dobrin PB, Littooy FN, Golan J, et al. Mechanical and histologic changes in canine vein grafts. J Surg Res. 1988;44:259-265.
26. Lemson MS, Tordoir JH, Daemen MJ, et al. Intimal hyperplasia in vascular grafts. Eur J Vasc Endovasc Surg. 2000;19:336-350.
27. Rashid ST, Salacinski HJ, Hamilton G, et al. The use of animal models in developing the discipline of cardiovascular tissue engineering: a review. Biomaterials. 2004;25:1627-1637.
28. Ferns GA, Raines EW, Sprugel KH, et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
29. Lemson MS, Daemen MJ, Kitslaar PJ, et al. A new animal model to study intimal hyperplasia in arteriovenous fistulas. J Surg Res. 1999;85:51-58.
30. Wu S, Wang X, Guo L, et al. Adenovirus mediated endothelial nitric oxide synthase gene transfer prevents restenosis of vein grafts. ASAIO J. 2004;50:272-277.
31. Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci U S A. 1990;87:3773-3777.
32. Lin PH, Chen C, Bush RL, et al. Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. J Vasc Surg. 2004;39:1322-1328.
33. Toes GJ, Barnathan ES, Liu H, et al. Inhibition of vein graft intimal and medial thickening by periadventitial application of a sulfated carbohydrate polymer. J Vasc Surg. 1996;23:650-656.
34. Schachner T, Zou Y, Oberhuber A, et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg. 2004;77:1580-1585.
35. Fulton GJ, Davies MG, Barber L, et al. Locally applied antisense oligonucleotide to proliferating cell nuclear antigen inhibits intimal thickening in experimental vein grafts. Ann Vasc Surg. 1998;12:412-417.
36. Petrofski JA, Hata JA, Gehrig TR, et al. Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia. J Thorac Cardiovasc Surg. 2004;127:27-33.
37. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003;107:517-520.